Canaccord raised the firm’s price target on Insulet (PODD) to $428 from $399 and keeps a Buy rating on the shares. The firm said Insulet delivered another strong beat-and-raise in Q3, driven by OUS outperformance and record new patient starts in US T1 and US T2.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD: